ScreenerHero

AEONAEON Biopharma Inc. Class A Common Stock

AMEX · US · Healthcare · Biotechnology · aeonbiopharma.com
0.1921USD-3.18%Mkt Cap: 9.58M $P/E: —

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 st…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.58M $
Enterprise Value8.93M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.22M $
Revenue/Share—
Last Price0.1921 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.77
PEG—
EV/EBITDA-0.45
EV/Revenue—
P/S—
P/B-0.33
EPS (TTM)-4.55
EPS (Forward)-0.25
52W Range
0.17971% of range1.450
52W High1.450 USD
52W Low0.1797 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE71.28%
ROA-705.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.31M $
CapEx (TTM)4.00K $
FCF Margin—
FCF Yield-75.00%
Net Debt-656.00K $
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity-0.65
Current Ratio0.54
Quick Ratio0.47
Book Value/Sh-0.5840 USD
Cash/Share0.0690 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:72
Split DateFeb 26, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.433 USD
Upside (mean)+646.1%
Target Range1.000 USD – 2.100 USD
$1.000+646.1% to mean$2.100
# Analysts3
Ownership
Shares Out.49.88M
Float30.51M
Insiders40.44%
Institutions32.75%
Short Interest
Short Ratio0.3d
Short % Float2.40%
Short % Out.1.80%
Shares Short876.97K
Short (prev mo.)160.27K
Technical
SMA 500.4342 (-55.8%)
SMA 2000.8445 (-77.3%)
Beta0.64
S&P 52W Chg19.18%
Avg Vol (30d)2.94M
Avg Vol (10d)3.04M
Technical Indicators
RSI (14)17.9
MACD-0.0729
MACD Signal-0.0810
MACD Hist.+0.0081
BB Upper0.3220 USD
BB Middle0.2650 USD
BB Lower0.2080 USD
BB Width43.02%
ATR (14)0.0356 USD
Vol Ratio (20d)0.93x